An observational study in Heart Diseases, sponsored by Occlutech International AB. Recruiting at 36 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Occlutech International AB · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Heart Diseases with a site in Turkey — 6 open to participants now, 8 under way, 2 of them phase 3. Heart Diseases · Turkey.
Among the 34 studies in Heart Diseases with a site in Turkey, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, and was the 12th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →6 of the 34 studies in Heart Diseases with a site in Turkey are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Turkey, Argentina, Australia and 35 more countries
Ages 50+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18+
P+F Products + Features GmbH · Sites in Turkey, Argentina, Brazil and 5 more countries
Ages 65+
Ahi Evran University Education and Research Hospital · Sites in Turkey
Ages 65+
Taewoong Medical Co., Ltd. · Sites in Turkey, Germany, Italy and 3 more countries
Ages 10+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 685 is above the median of 350 across 592 observational studies indexed under Heart Diseases.
Median enrollment 70 across the 23 interventional studies, 239 across the 11 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 34 have an industry lead sponsor. The 10 most frequent:
Occlutech International AB is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
Occlutech International AB has 1 study filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Diseases with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05174442Occlutech International ABACCESS Registry: A Post Market Follow-up Study to Monitor the Safety, Performance and Usability of Occlutech Accessory Medical Devices | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Heart Diseases with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The registry is an international, multicenter, non-randomized, non-invasive study to assess the safety, performance and usability of the Occlutech Accessories "Occlutech Delivery Set (ODS), Occlutech Pistol Pusher (OPP), Occlutech Occlusions-Pusher (OOP) and Occlutech Sizing Balloon (OSB)" used for implantation procedures (catheter-based interventions) of cardiac implants via completing surveys (questionnaires) for the accessory medical devices by the investigators.
The registry is an international, multicenter, non-randomized, non-invasive study to assess the safety, performance and usability of the Occlutech Accessories "Occlutech Delivery Set (ODS), Occlutech Pistol Pusher (OPP), Occlutech Occlusions-Pusher (OOP) and Occlutech Sizing Balloon (OSB)" used for implantation procedures (catheter-based interventions) of cardiac implants via completing surveys (questionnaires) for the accessory medical devices by the investigators.
A survey (questionnaire) of each accessory medical device should be completed by investigator in order to assess safety of the accessory by success of implantation procedure, occurrence of adverse events during implantation procedure or as late term effects resulting from implantation procedure, user harm related to the accessory, procedure, reported device deficiencies related to the accessory. The Surveys (questionnaires) also include questions related to performance, usability and compatibility with devices and other accessories. Subjects should be treated according to instructions-for-use of the implants and accessories and according to clinical routine. The devices must have been used exclusively by physicians who are experienced in cardiac catheterization techniques and who are experienced in using the products in the process of interventional operations.
All subjects who underwent implantation procedure with an Occlutech accessory medical device and cardiac implants can be included. Preconditions depend exclusively on the requirements outlined in the applicable Instruction for Use of the implant and the accessories.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects who underwent implantation procedure with an Occlutech accessory medical device and cardiac implants can be included
Exclusion Criteria:
Occurence of safety events
The primary safety endpoint is defined as the rate of incidences of (peri-) procedural adverse events / rate of (serious) adverse device effects ((S)ADEs) during implantation or as late effects of implantation procedure. A serious adverse device effect (SADE) is defined as an event that is clearly caused by the device such as: * device dislocation (during the procedures with OPP, OOP,ODS) * embolization related with procedure and accessories * Late effect of implantation procedure: damage to the vessels and heart caused by the accessories * any circumstances that require device removal related with procedure or accessories used during the implantation * Signs of thrombosis
Time frame: 6 months
Performance, usability:
will be assessed in terms of mechanical performance, procedural data by completing the survey (questionnaire) for each accessory with grading. Compatibility of ODS, OPP, OOP with cardiac implant devices or/and other accessory medical devices.
Time frame: 6 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started Oct 2021 (actual). Primary completion is estimated for Jan 2027, 62 months after the start.
Of 54 industry-sponsored observational studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 65. This study's planned 62 months is above that.
Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Occlutech International AB